Evidence map›Paper›PMID 26960557›Full record

ArticleJIMD reports2016

A Founder Effect for the HGD G360R Mutation in Italy: Implications for a Regional Screening of Alkaptonuria.

Berardino Porfirio, Roberta Sestini, Greta Gorelli, Miriam Cordovana, Alessandro Mannoni, Jeanette L Usher, Wendy J Introne, William A Gahl, Thierry Vilboux

Open access · greenAbstract read
In one paragraph

Article in JIMD reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Combined alkaptonuria and osteoporosis contributing to chronic back pain.Endocrinology, diabetes & metabolism case reports · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Berardino PorfirioDepartment of Clinical and Experimental Biomedical Sciences "Mario Serio", Clinical Physiopathology Unit, University of Florence, Viale Gaetano Pieraccini 6, 50139, Florence, Italy. nporfirio@unifi.it.
Roberta SestiniDepartment of Clinical and Experimental Biomedical Sciences "Mario Serio", Clinical Physiopathology Unit, University of Florence, Viale Gaetano Pieraccini 6, 50139, Florence, Italy.
Greta GorelliDepartment of Clinical and Experimental Biomedical Sciences "Mario Serio", Clinical Physiopathology Unit, University of Florence, Viale Gaetano Pieraccini 6, 50139, Florence, Italy.
Miriam CordovanaDepartment of Clinical and Experimental Biomedical Sciences "Mario Serio", Clinical Physiopathology Unit, University of Florence, Viale Gaetano Pieraccini 6, 50139, Florence, Italy.
Alessandro MannoniInternal Medicine Division, Rheumatology Unit, Ospedali S. Maria Nuova e Palagi, ASL 10 Firenze, Florence, Italy.
Jeanette L UsherDepartment of Clinical Biochemistry and Metabolic Medicine, Royal Liverpool and Broadgreen University Hospital Trust, Liverpool, UK.
Wendy J IntroneMedical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
William A GahlMedical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
Thierry VilbouxMedical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
University of Florence · ITNational Institutes of Health · USOffice of the Director · USRoyal Liverpool and Broadgreen University Hospital NHS Trust · GB

Funding

NHGRI/DIR Clinical Support ServicesZIDHG200352 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI SOLOMON, BENJAMIN · 2009 to 2025
$182.8M
Human Biochemical GeneticsZIAHG000215 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI GAHL, WILLIAM · 2009 to 2025
$72.6M
6 · The paper itself

Abstract

We sought to establish rapid and specific genotyping methods for G360R mutation and for seven tightly linked markers in the homogentisate dioxygenase gene to address the question of whether G360R is a mutational hot spot or the result of a founder effect, as it has been repeatedly found in alkaptonuric patients from a geographic isolate in Italy.For G360R and single nucleotide polymorphism genotyping, high-resolution melting analysis was performed. Microsatellites were analysed by multiplex PCR and capillary electrophoresis. To investigate the natural history of the G360R mutation, we genotyped markers in 52 controls and in 8 unrelated patients from the UK and USA, who also segregated the G360R mutation, and calculated its age using DMLE+2.3 software.A distinct G360R-bearing haplotype was identified in all patients of Caucasian descent. Estimated mutation age was 545 generations (95% credible set, 402-854), suggesting that G360R arose in an ancestor who lived 8,000-10,000 years BC. Archaeological, historical and demographic data support that a G360R carrier has settled the remote valley where present-day population might have a heterozygote frequency of at least 6%.Given the late health-threatening complications of alkaptonuria and a cure within reach, inhabitants of this isolate would benefit from screening and genetic counselling.

Indexed as

AlkaptonuriaFounder effectGenetic screeningMutation ageOchronosis

Identifiers

PMID26960557
PMCPMC5110449
OpenAlexW2301799307

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.